Maxine Ingham, MD
Family Medicine · Las Vegas, NVNPI 1730294455
Payments from drug & device makers
Across 129 payments — averaging $22,501 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rhodes Pharmaceuticals L.p.$1.3M
- Apotex Inc.$468K
- Aquestive Therapeutics, Inc.$443K
- Alvogen Inc$383K
- USWM, LLC$264K
- Boehringer Ingelheim$20K
- plus $13K from 30 others
Across 3 payments — averaging $198,906 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Kindeva Drug Delivery L.p.$476K
- Aquestive Therapeutics, Inc.$120K
What the payments were for
- Food & beverage$5,787100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rhodes Pharmaceuticals L.p. | 8 | $1,309,758 |
| Apotex Inc. | 5 | $468,263 |
| Aquestive Therapeutics, Inc. | 8 | $443,133 |
| Alvogen Inc | 6 | $383,429 |
| USWM, LLC | 5 | $264,370 |
| Boehringer Ingelheim | 2 | $20,392 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $6,677 |
| AbbVie | 9 | $907 |
| Amgen(2 entities) | 8 | $842 |
| Boehringer Ingelheim International GmbH | 9 | $767 |
| Biogen | 17 | $648 |
| Regeneron Healthcare Solutions, Inc. | 4 | $440 |
| Novo Nordisk | 3 | $356 |
| UCB, Inc. | 8 | $310 |
| AstraZeneca(2 entities) | 2 | $243 |
| Lucid Diagnostics Inc. | 1 | $241 |
| Novartis | 2 | $143 |
| Galderma Laboratories, L.p. | 1 | $142 |
| Teva Pharmaceuticals USA, Inc. | 2 | $142 |
| Kyowa Kirin, Inc. | 2 | $142 |
| Gilead | 2 | $137 |
| Lilly USA, LLC | 5 | $132 |
| Biohaven Pharmaceuticals, Inc. | 1 | $126 |
| Incyte Corporation | 1 | $124 |
| Sanofi | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $120 |
| GSK | 1 | $119 |
| MDD US Operations, LLC | 1 | $88 |
| Jazz Pharmaceuticals Inc. | 3 | $59 |
| Johnson & Johnson | 2 | $53 |
| Genentech USA, Inc. | 3 | $36 |
| Indivior Inc. | 1 | $34 |
| GE HealthCare | 1 | $29 |
| Eisai Inc. | 1 | $24 |
| Pfizer | 1 | $16 |
| Impel Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,902,575 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Alcohol Prep PadsAlcohol Antiseptic Pads | 15 | $392 |
| Losartan Potassium | 31 | $84 |
| Omeprazole | 13 | $44 |
| Chlorthalidone | 11 | $42 |
| Levothyroxine Sodium | 12 | $36 |
| Atorvastatin Calcium | 12 | $30 |
| Metformin Hcl | 17 | $28 |
| Hydrochlorothiazide | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Las Vegas
- Rogelio MachucaLas Vegas$3.3M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
- Peter PhilanderLas Vegas$524K
- Jerry CadeLas Vegas$381K
- Dana ForteLas Vegas$169K
- Francisco MachucaLas Vegas$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.